Third patient implanted with Ventracor device
Thursday, 23 October, 2003
Ventracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
According to the chief medical investigator Prof Don Esmore, the patient is in a critical but stable condition.
He said the patient was gravely ill at the time of the procedure, and the implant was the only option available.
The announcement comes a couple of weeks after the second patient to receive the implant was discharged from hospital. The company plans to test up to ten patients in the pilot trial, before embarking on a larger, international trial.
Ventracor's share price rose four per cent yesterday after the announcement was made to close at AUD$2.49.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
